01-26-01

1

je951 U.S.

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 13070-1

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

	wasnington, D.C. 2023 i
Transmitted he	rewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an
invention entitle	
Method for tl	he Evaluation of Implantable Materials
and invented by	V'
	G, Shahrokh, SZALAY, Aladar A. and YU, Yong
	o, blantokii, ozzazati, maari isi ana to, tong
If a CONTINU	ATION APPLICATION, check appropriate box and supply the requisite information:
☐ Continua	tion Divisional Continuation-in-part (CIP) of prior application No.: 60/178,538
Which is a:	
☐ Continua	tion Divisional Continuation-in-part (CIP) of prior application No.:
Which is a:	— Divisional — Communicion in part (cir.)— Si prior approximentos
☐ Continua	ition Divisional Continuation-in-part (CIP) of prior application No.:
Enclosed are:	Application Floresum
	Application Elements
1. 🛭 Fili	ng fee as calculated and transmitted as described below
2. 🗵 Sp	ecification having16 pages and including the following:
a. 🛚	Descriptive Title of the Invention
b. 🛚	Cross References to Related Applications (if applicable)
c. 🗆	Statement Regarding Federally-sponsored Research/Development (if applicable)
4 0	
d. 🗆	Reference to Microfiche Appendix (if applicable)
e. 🛚	Background of the Invention
f. 🛛	Brief Summary of the Invention
g. 🛛	Brief Description of the Drawings (if drawings filed)
_	
h. 🛚	Detailed Description
i. 🛚	Claim(s) as Classified Below
j. 🛛	Abstract of the Disclosure
j. 🔀	Abstract of the Disclosure

the Ball will find the last the first that the first that the think the think the

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

Docket No. 13070-1

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

Application Elements (Continued)										
3.	3. Drawing(s) (when necessary as prescribed by 35 USC 113)									
	a.									
4.	X	Oath or Declaration								
	a.	Newly executed (original or copy) □ Unexecuted								
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)								
	c.	☑ With Power of Attorney ☐ Without Power of Attorney								
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).								
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.								
6.		Computer Program in Microfiche								
7.		Genetic Sequence Submission (if applicable, all must be included)								
	a.	□ Paper Copy								
	b.	□ Computer Readable Copy								
	C.	☐ Statement Verifying Identical Paper and Computer Readable Copy								
		Accompanying Application Parts								
8.	X	Assignment Papers (cover sheet & documents)								
9.		37 CFR 3.73(b) Statement (when there is an assignee)								
10.		English Translation Document (if applicable)								
11.	×	Information Disclosure Statement/PTO-1449 Copies of IDS Citations								
12.		Preliminary Amendment								
13.	×	Acknowledgment postcard								
14.	×	Certificate of Mailing								
		☐ First Class ☒ Express Mail (Specify Label No.): EL442633424US								

the difference with the property of the proper

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 13070-1

Total Pages in this Submission

	Accompanying Application Parts (Continued)						
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)					
16.		Small Entity Statement(s) - Specify Number of Statements Submitted:					
17.		Additional Enclosures (please identify below):					
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)					
18.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.					
Warning							
An applicant who makes a request not to publish, but who subsequently files in a factorized country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2 must notify the Director of such filing not later than 45 days after the date of the files such foreign or international application. A failure of the applicant to provide such within the prescribed period shall result in the application being regarded as abandunless it is shown to the satisfaction of the Director that the delay in submitting the was unintentional.							

Page 3 of 4

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 13070-1

Total Pages in this Submission
4

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra		Rate	Fee
Total Claims	22	- 20 =	2	x	\$9.00	\$18.00
Indep. Claims	2	- 3 =	0.	x	\$40.00	\$0.00
Multiple Dependent Claims (check if applicable)					\$0.00	
					BASIC FE	\$355.00
OTHER FEE (specify purpose)						\$0.00
					TOTAL FILING FE	\$373.00

23	A checi	k in the amount of	\$3/3.00	to cover the filling fee is enclosed.					
X	The Commissioner is hereby authorized to charge and credit Deposit Account No. 19-209								
	as described below. A duplicate copy of this sheet is enclosed.								
		Charge the amount	of	as filing fee.					
	\boxtimes	Credit any overpayr	ment.						
☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.									
		Charge the issue fe	e set in 37 C.F.	R. 1.18 at the mailing of the Notice of Allo	wance,				

pursuant to 37 C.F.R. 1.311(b).

Dated: January 25, 2001

Signature

David A. Farah, M.D.

cc: